目的 探讨莫沙必利联合奥美拉唑镁治疗反流性食管炎的临床疗效。方法 选取2020年6月-2022年7月在延安大学附属医院诊治的104例反流性食管炎患者，随机分为对照组和治疗组，每组各52例。对照组口服艾司奥美拉唑镁肠溶片，20 mg/次，2次/d；治疗组在对照组基础上口服枸橼酸莫沙必利片，2 mg/次，3次/d。两组患者均连续治疗2个月。观察两组患者临床疗效，比较治疗前后两组患者胃肠激素（GAS）和胃动素（MTL）水平及炎性因子白细胞介素-4（IL-4）、IL-7和IL-17水平，血清血红素氧合酶-1（HO-1）和瘦素水平。结果 治疗后，治疗组总有效率明显高于对照组（94.23%vs 76.92%，P<0.05）。治疗后，两组GAS、MTL和IL-4水平明显升高，而IL-7、IL-17、HO-1和瘦素水平明显降低（P<0.05），且治疗组这些指标水平明显好于对照组（P<0.05）。结论 莫沙必利联合奥美拉唑镁治疗反流性食管炎具有理想效果，不仅能调整胃肠激素，并且能降低炎性因子及HO-1、瘦素表达，且安全性高。
Objective To investigate the effects of mosorapride combined with magnesium omeprazole in treatment of reflux esophagitis. Methods Patients (104 cases) with reflux esophagitis in Yan'an University Affiliated Hospital from June 2020 to Junly 2022 were randomly divided into control and treatment group, and each group had 52 cases. Patients in the control group were po administered with Esomeprazole Magnesium Enteric-coated Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Mosapride Citrate Tablets on the basis of the control group, 2 mg/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical evaluation was evaluated, and the levels of GAS, MTL, IL-4, IL-7, IL-17, HO-1, and leptin in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (94.23% vs 76.92%, P < 0.05). After treatment, the levels of GAS, MTL, and IL-4 were significantly increased, while the levels of IL-7, IL-17, HO-1, and leptin were significantly decreased in two groups (P < 0.05), and the levels of these indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Mosapride combined with magnesium omeprazole is effective in treatment of reflux esophagitis. It can not only regulate gastrointestinal hormones, but also reduce the expression of inflammatory factors and HO-1 and leptin.